Chime Biologics and Arbele announce strategic collaboration at BIOHK 2025 signing ceremony

CAR-T Digest - August 2020

11 September 2025: Chime Biologics and Arbele announce strategic collaboration at BIOHK 2025 signing ceremony

Chime Biologics and Arbele signed a strategic collaboration agreement at BIOHK 2025 to advance innovative antibody-drug conjugate (ADC) therapies
Their first joint project is an IND program for a CDH17-targeted ADC, with plans to develop additional ADCs against the same target using Chime Biologics’ proprietary high-throughput PCC screening platform
Arbele announced plans to expand its operations in Biolake, Wuhan, to tap into the region’s biopharma talent and infrastructure, accelerating its pipeline development in China
Under this strategy, Arbele is also exploring collaborations with local hospitals, research institutes and companies to drive innovative R&D
Executives from both companies highlighted that the partnership combines Chime Biologics’ world-class CDMO capabilities with Arbele’s innovative pipeline, aiming to speed delivery of transformative ADC therapies and exemplify cross-border biopharma innovation